Overview

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating pain in patients with painful diabetic peripheral neuropathy
Phase:
Phase 2
Details
Lead Sponsor:
Allergan